These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 23298940)

  • 1. Titrated dose of drotrecogin alpha for liver transplant recipient.
    Saluja V; Pandey V; Pandey CK; Singhal A
    J Postgrad Med; 2012; 58(4):330-1. PubMed ID: 23298940
    [No Abstract]   [Full Text] [Related]  

  • 2. Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis.
    Kulkarni S; Naureckas E; Cronin DC
    Transplantation; 2003 Mar; 75(6):899-901. PubMed ID: 12660522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of drotrecogin alfa (activated) in a patient with recent orthotopic liver transplant.
    Browne E; Cressey DM; Agarwal K; Cosgrove JF
    Anaesthesia; 2007 Mar; 62(3):282-5. PubMed ID: 17300307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Readministration of drotrecogin alpha in a patient with Crohn's disease].
    Cid Conde L; Varela Correa JJ; Padrón Gil C
    Farm Hosp; 2006; 30(3):193-5. PubMed ID: 16999567
    [No Abstract]   [Full Text] [Related]  

  • 5. [Re-administration of drotrecogin alpha].
    Romero B; García-Martínez MA; Solera M; Alvarez B
    Med Intensiva; 2009; 33(5):261-2. PubMed ID: 19625004
    [No Abstract]   [Full Text] [Related]  

  • 6. The rise and fall of drotrecogin alfa (activated).
    Vincent JL
    Lancet Infect Dis; 2012 Sep; 12(9):649-51. PubMed ID: 22809884
    [No Abstract]   [Full Text] [Related]  

  • 7. A new tool for fighting sepsis.
    Devlin MM
    Nurs Manage; 2004; Suppl():33-5. PubMed ID: 15303508
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
    Kalil AC; LaRosa SP
    Lancet Infect Dis; 2012 Sep; 12(9):678-86. PubMed ID: 22809883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus Peritonitis Without Gut Perforation But With Concomitant Colitis After a Liver Allograft Transplant.
    Lankarani KB; Taghavi SA; Pahlavan Sabbagh MR; Malek-Hosseini SA
    Exp Clin Transplant; 2017 Feb; 15(1):106-109. PubMed ID: 26134882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drotrecogin alpha and anticoagulants in septic patients after cardiac surgery.
    Pappalardo F; Cristallo E; Franco A; Antonioli G; Zangrillo A
    Eur J Anaesthesiol; 2007 Mar; 24(3):294-5. PubMed ID: 17054810
    [No Abstract]   [Full Text] [Related]  

  • 11. Outcomes of patients with cytomegalovirus viremia at the time of liver transplantation.
    Bruminhent J; Razonable RR
    Liver Transpl; 2014 Sep; 20(9):1029-33. PubMed ID: 24838342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drotrecogin alfa (activated) in severe sepsis.
    Poole D; Rossi C; Addis A; Livigni S; Bertolini G
    Lancet Infect Dis; 2013 Feb; 13(2):107-8. PubMed ID: 23347624
    [No Abstract]   [Full Text] [Related]  

  • 13. Drotrecogin alfa (activated) in severe sepsis.
    Marik PE
    Lancet Infect Dis; 2013 Feb; 13(2):107. PubMed ID: 23347625
    [No Abstract]   [Full Text] [Related]  

  • 14. Drotrecogin alfa (activated) in severe sepsis.
    Janes JM; Vangerow B; Costigan TM; Macias WL
    Lancet Infect Dis; 2013 Feb; 13(2):108-9. PubMed ID: 23347626
    [No Abstract]   [Full Text] [Related]  

  • 15. Drotrecogin alfa (activated) in severe sepsis.
    Gayat E; Lemasle L; Payen D
    Lancet Infect Dis; 2013 Feb; 13(2):109-10. PubMed ID: 23347627
    [No Abstract]   [Full Text] [Related]  

  • 16. Quantitative CMV-antigenemia test in the diagnosis of CMV infection and in the monitoring of response to antiviral treatment in liver transplant recipients.
    Lautenschlager I; Höckerstedt K; Salmela K
    Transplant Proc; 1994 Jun; 26(3):1719-20. PubMed ID: 8030100
    [No Abstract]   [Full Text] [Related]  

  • 17. Timing of drotrecogin alfa (activated) treatment in severe sepsis.
    Choi G; de Pont AC; Schultz MJ
    Crit Care; 2006; 10(4):419; author reply 419. PubMed ID: 16934134
    [No Abstract]   [Full Text] [Related]  

  • 18. Drotrecogin alfa (activated) in severe sepsis--authors' reply.
    Kalil AC; LaRosa SP
    Lancet Infect Dis; 2013 Feb; 13(2):110-1. PubMed ID: 23347628
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis.
    Macias WL; Dhainaut JF; Yan SC; Helterbrand JD; Seger M; Johnson G; Small DS
    Clin Pharmacol Ther; 2002 Oct; 72(4):391-402. PubMed ID: 12386641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus disease after liver transplantation: diagnostics and therapy.
    Wiens M; Schmidt CA; Lohmann R; Oettle H; Blumhardt G; Neuhaus P
    Transplant Proc; 1993 Aug; 25(4):2673-4. PubMed ID: 8395108
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.